New triple therapy aims to wipe out head and neck tumors before surgery

NCT ID NCT07393477

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery can shrink or eliminate tumors in people with advanced head and neck cancer. About 30 adults aged 18-70 with stage III/IVA disease who have not had prior treatment will receive the therapy for 6-12 weeks. Researchers will check how many patients have no cancer cells left after treatment and how long they stay cancer-free.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••